Skip to main content

New Analysis Reveals Most Patients Discontinue Weight Loss Drugs Within First Year

By: PRLog
PreventiveMedicineDaily.com Publishes Comprehensive Review on GLP-1 Medication Persistence Rates Despite Long-Term Treatment Recommendations

FRESNO, Calif. - Jan. 11, 2026 - PRLog -- PreventiveMedicineDaily.com has published a comprehensive analysis revealing that despite being designed for long-term use, most patients discontinue GLP-1 weight loss medications within the first year of treatment. The detailed review, supervised by Jose Rossello, MD, PhD, MCHM, examines real-world persistence data from 2024-2025 and highlights a significant gap between clinical recommendations and patient adherence patterns.

According to the comprehensive analysis published in "How Long Are People on Weight Loss Drugs?", only 40-63% of patients remain on GLP-1 medications at 12 months, with persistence rates dropping to approximately 15-25% at two years. The review examined multiple medications including semaglutide versus tirzepatide, and liraglutide (Saxenda), finding that once-weekly formulations demonstrate better persistence than daily injections. At the six-month mark, approximately 47% of patients remain on treatment, representing a critical period when many face challenges with side effects, cost, or insurance coverage changes.

"This disconnect between recommended long-term use and actual patient persistence raises important questions about treatment expectations, affordability, and support systems," according to the PreventiveMedicineDaily.com analysis. The review emphasizes that clinical guidelines recommend GLP-1 medications as chronic disease management tools with no maximum duration restrictions, yet real-world data consistently shows early discontinuation followed by significant weight regain in most patients.

The analysis identifies multiple factors contributing to early discontinuation, including medication costs averaging $900-$1,300 per month without insurance, gastrointestinal side effects, and widespread misperceptions of GLP-1 medications as short-term solutions. The review also highlights that newer medications like tirzepatide show improved persistence rates (55-73% at six months) compared to earlier GLP-1 formulations.

"Understanding real-world persistence patterns is essential for patients and healthcare providers to set realistic expectations and plan for long-term success," notes the PreventiveMedicineDaily.com editorial team. "Our goal is to provide evidence-based information that helps readers make informed decisions about preventive care and weight management strategies."

Related articles:

Natural GLP-1 Boosters

What Tea Is Best for Weight Loss

Caloric Needs Calculator (Interactive tool)


Contact
Jose Rossello (Owner)
Preventive Medicine Daily
***@preventivemedicinedaily.com

Photos: (Click photo to enlarge)

Weight Loss Medication Retention Rates


Source: Preventive Medicine Daily

Read Full Story - New Analysis Reveals Most Patients Discontinue Weight Loss Drugs Within First Year | More news from this source

Press release distribution by PRLog

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.44
+3.17 (1.55%)
AAPL  271.83
+5.65 (2.12%)
AMD  213.73
+17.13 (8.71%)
BAC  50.42
-0.65 (-1.27%)
GOOG  311.01
-0.68 (-0.22%)
META  638.24
+0.99 (0.15%)
MSFT  388.05
+3.58 (0.93%)
NVDA  192.94
+1.39 (0.73%)
ORCL  145.72
+4.41 (3.12%)
TSLA  409.46
+9.63 (2.41%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.